Study data showed the drug crenezumab did not meet its primary endpoint in reducing cognitive decline in mild to moderate Alzheimer's disease patients when compared with a placebo, but Cleveland Clinic researchers said it may be effective for a subset of patients with the mildest symptoms. The data mirror earlier research on a similar drug, solanezumab, which now is being tested in preclinical Alzheimer's patients.

Related Summaries